Evidence map›Paper›PMID 31144158›Full record

ArticleJournal of cancer research and clinical oncology2019

HALFMOON TomoTherapy (Helical ALtered Fractionation for iMplant partial OmissiON): implant-sparing post-mastectomy radiotherapy reshaping the clinical target volume in the reconstructed breast.

Maria Cristina Leonardi, Ruggero Spoto, Eleonora Miglietta, Sara Trivellato, Eliana La Rocca, Rosa Luraschi, Paola Grosso, Francesca De Lorenzi, Cristiana Fodor, Samantha Dicuonzo and 10 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Maria Cristina LeonardiDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Ruggero SpotoDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Eleonora MigliettaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Sara TrivellatoUnit of Medical Physics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Eliana La RoccaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Rosa LuraschiUnit of Medical Physics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Paola GrossoUnit of Medical Physics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Francesca De LorenziDivision of Plastic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Cristiana FodorDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Samantha DicuonzoDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. samantha.dicuonzo@ieo.it.ORCID http://orcid.org/0000-0003-4275-0080
Veronica Dell'AcquaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Marianna Alessandra GerardiDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Anna MorraDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Claudia Maria FranciaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Mario RietjensDivision of Plastic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Viviana Enrica GalimbertiDivision of Breast Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Paolo VeronesiDepartment of Oncology and Hemato-oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
Roberto OrecchiaScientific Direction, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Federica CattaniUnit of Medical Physics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Barbara Alicja Jereczek-FossaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Ripamonti · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Milan · ITEuropean Institute of Oncology · IT

Funding

Accuray Inc analysis of TomotherapyAccuray Inc CyberKnife breast clinical studies, breast physics studiesAccuray Inc grant for Data collectionAccuray Inc prostate studyIEO Foundation (FIEO) fellowship for Helical ALtered Fractionation for iMplant partial OmissiON): Implant sparing helical tomotherapy with hypofractionated scheme for intermediate/high risk breast cancer
6 · The paper itself

Abstract

purposeTo report the dosimetric feasibility of the radiation technique HALFMOON (Helical ALtered Fractionation for iMplant partial OmissiON) for post-mastectomy radiation therapy (PMRT) in intermediate-high-risk breast cancer patients with implant-based immediate breast reconstruction, where the clinical target volume (CTV) does not include the whole implant (implant-sparing approach).

methodsIn the HALFMOON technique, the CTV consisted of skin, subcutaneous tissues, and pectoralis major muscle, excluding the implant, chest wall muscles, and rib plane. The HALFMOON plans were compared with conventionally contoured CTV plans, in which the whole implant, chest wall muscles, and ribs plane were included in the CTV, in a ratio 1:3. All patients underwent hypofractionated treatment of 40.05 Gy/15 fractions, using helical Tomotherapy

resultsEighteen patients undergoing HALFMOON technique were compared to 54 subjects treated with conventionally contoured CTV plans. No difference was found in the planning target volume coverage between the two groups. Conversely, a statistically relevant dose reduction in HALFMOON patients was observed for ipsilateral lung (D

conclusionThe HALFMOON approach is technically feasible and resulted in high-dose conformity of the target with a significant reduction of radiation dose delivered to implant and other organs. A clinical study is needed to assess the impact on reconstruction cosmetic outcome and local control.

Indexed as

Breast ImplantsBreast NeoplasmsCase-Control StudiesCohort StudiesFemaleHumansMastectomyMiddle AgedPilot ProjectsProspective StudiesRadiation Dose HypofractionationRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedTomography, X-Ray ComputedDosimetryHypofractionationImmediate breast reconstructionIntensity-modulated radiotherapyPost-mastectomy radiation therapy

Identifiers

PMID31144158
PMCPMC11810379
OpenAlexW2947508195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.